The Latest Breaking News from NICE

The best managers in the world, from the tinkermen to the tacticos and everyone in between

ANALYSIS: Paul Atkinson and Sally Sheard say the decision reflects a cautious and evidence-based approach that protects patients and public funds

The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for routine NHS use in England. While disappointing for some families affected by dementia, this decision reflects a cautious and evidence-based approach that protects patients and public funds.

IN FULL

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.

Treating lower back pain is enormously expensive. In the UK it’s estimated to cost the NHS around £3.2 billion a year. So, ensuring patients get the right treatment is critical.

IN FULL

Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has said

‘It’s so close – and yet we’re stuck,’ says mother of twins with rare muscular disorder

It's a blunder for Manchester United owners INEOS on this occasion

Some 614,000 adults in England are affected by heart failure.